Seaport Therapeutics, a Phase 2 biotech developing therapies for neuropsychiatric indications, announced terms for its IPO on Monday.
The Boston, MA-based company plans to raise $201 million by offering 11.8 million shares at a price range of $16 to $18. General Atlantic intends to purchase $50 million worth of shares in the offering (25% of the deal).
Seaport Therapeutics is a clinical-stage biotechnology company developing oral therapies for neuropsychiatric disorders, including depression, anxiety, and other central nervous system conditions. The company uses its proprietary Glyph platform, a lymphatic-targeting prodrug technology designed to improve oral bioavailability and reduce first-pass metabolism, to reformulate clinically validated mechanisms into differentiated product candidates. Its lead programs include GlyphAllo in Phase 2b for major depressive disorder and GlyphAgo in Phase 1 for generalized anxiety disorder, with additional preclinical candidates targeting depressive and related CNS disorders.
Seaport Therapeutics was founded in 2024. It plans to list on the Nasdaq under the symbol SPTX. Goldman Sachs, J.P. Morgan, Leerink Partners, Citi, and Stifel are the joint bookrunners on the deal. It is expected to price the week of April 27, 2026.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.